Dilraj S Grewal1, Glenn J Jaffe1, Robert T Keenan2. 1. Department of Ophthalmology, Duke University, Durham, North Carolina; and. 2. Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
Abstract
PURPOSE: To demonstrate a rapid improvement of recalcitrant cystoid macular edema (CME) and perivascular leakage, in a patient with non-paraneoplastic autoimmune retinopathy and autoimmune optic neuropathy after treatment with sarilumab, a human anti-interleukin-6 (IL-6) receptor antibody. METHODS: Observational case report. RESULTS: A 29-year-old woman was diagnosed with non-paraneoplastic autoimmune retinopathy and autoimmune optic neuropathy and followed over 1.5 years. She had recalcitrant CME despite local corticosteroid and immunosuppressive therapy that included azathioprine and adalimumab. Subcutaneous sarilumab was initiated at a dose of 200 mg every 2 weeks. Cystoid macular edema significantly decreased after two injections and resolved after four injections with associated improvement in visual acuity and significant improvement in perivascular leakage on fluorescein angiography. There was a sustained visual and anatomical improvement at 6 months along with mild improvement in electroretinogram responses. The patient tolerated the medication with no side effects. CONCLUSION: Management of CME in non-paraneoplastic autoimmune retinopathy is challenging, and long-term immunosuppression is often employed with varying degrees of success. The improvement in refractory CME and perivascular leakage in this case supports the potential role of an IL-6 inhibitor to treat CME associated with non-paraneoplastic autoimmune retinopathy suggesting the role.
PURPOSE: To demonstrate a rapid improvement of recalcitrant cystoid macular edema (CME) and perivascular leakage, in a patient with non-paraneoplastic autoimmune retinopathy and autoimmune optic neuropathy after treatment with sarilumab, a human anti-interleukin-6 (IL-6) receptor antibody. METHODS: Observational case report. RESULTS: A 29-year-old woman was diagnosed with non-paraneoplastic autoimmune retinopathy and autoimmune optic neuropathy and followed over 1.5 years. She had recalcitrant CME despite local corticosteroid and immunosuppressive therapy that included azathioprine and adalimumab. Subcutaneous sarilumab was initiated at a dose of 200 mg every 2 weeks. Cystoid macular edema significantly decreased after two injections and resolved after four injections with associated improvement in visual acuity and significant improvement in perivascular leakage on fluorescein angiography. There was a sustained visual and anatomical improvement at 6 months along with mild improvement in electroretinogram responses. The patient tolerated the medication with no side effects. CONCLUSION: Management of CME in non-paraneoplastic autoimmune retinopathy is challenging, and long-term immunosuppression is often employed with varying degrees of success. The improvement in refractory CME and perivascular leakage in this case supports the potential role of an IL-6 inhibitor to treat CME associated with non-paraneoplastic autoimmune retinopathy suggesting the role.
Authors: Jarmila Heissigerová; David Callanan; Marc D de Smet; Sunil K Srivastava; Michala Karkanová; Olga Garcia-Garcia; Sibel Kadayifcilar; Yilmaz Ozyazgan; Robert Vitti; Kristine Erickson; Aditya Athanikar; Karen Chu; Namrata Saroj; Preethi A Sundaram; Rafael Varona; Valerie Corp-Dit-Genti; Ronald Buggage; Yenchieh Cheng; Yuhwen Soo; Quan Dong Nguyen Journal: Ophthalmology Date: 2018-10-11 Impact factor: 12.079
Authors: Mark C Genovese; Roy Fleischmann; Alan J Kivitz; Maria Rell-Bakalarska; Renata Martincova; Stefano Fiore; Patricia Rohane; Hubert van Hoogstraten; Anju Garg; Chunpeng Fan; Janet van Adelsberg; Steven P Weinstein; Neil M H Graham; Neil Stahl; George D Yancopoulos; Tom W J Huizinga; Désirée van der Heijde Journal: Arthritis Rheumatol Date: 2015-06 Impact factor: 10.995
Authors: Avni P Finn; Akshay S Thomas; Sandra S Stinnett; Robert T Keenan; Dilraj S Grewal; Glenn J Jaffe Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-08-20 Impact factor: 3.117
Authors: Victor L Perez; George N Papaliodis; David Chu; Fahd Anzaar; William Christen; C Stephen Foster Journal: Ocul Immunol Inflamm Date: 2004-09 Impact factor: 3.070
Authors: Gerd R Burmester; Yong Lin; Rahul Patel; Janet van Adelsberg; Erin K Mangan; Neil M H Graham; Hubert van Hoogstraten; Deborah Bauer; Juan Ignacio Vargas; Eun Bong Lee Journal: Ann Rheum Dis Date: 2016-11-17 Impact factor: 19.103
Authors: Roy Fleischmann; Janet van Adelsberg; Yong Lin; Geraldo da Rocha Castelar-Pinheiro; Jan Brzezicki; Pawel Hrycaj; Neil M H Graham; Hubert van Hoogstraten; Deborah Bauer; Gerd R Burmester Journal: Arthritis Rheumatol Date: 2017-02 Impact factor: 10.995